Literature DB >> 14615657

Colinearity of reverse transcriptase inhibitor resistance mutations detected by population-based sequencing.

Matthew J Gonzales1, Elizabeth Johnson, Kathryn M Dupnik, Tomozumi Imamichi, Robert W Shafer.   

Abstract

High-level resistance to multiple drugs is often detected by directly sequencing uncloned polymerase chain reaction products (population-based sequencing). It is not known, however, if this method of identifying mutations gives an accurate picture of individual viral genomes. To determine how often multidrug-resistant isolates consist of clones containing every mutation present in the population-based sequence, a mean of 2.8 molecular clones was sequenced from the plasma of 25 heavily treated persons whose population-based sequence contained multiple reverse transcriptase (RT) inhibitor resistance mutations (71 clones). The 25 population-based sequences contained a mean of 5.7 nucleoside reverse transcriptase inhibitor (NRTI) resistance mutations and 1.2 nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance mutations. The 71 clones contained a mean of 5.3 NRTI resistance mutations and 1.0 NNRTI resistance mutations. Sequences of clones closely resembled the population-based sequence: 36 (51%) clones had each of the RT inhibitor mutations present in the population-based sequence, 25 (35%) had all but 1 RT inhibitor mutation, 4 (6%) had all but 2 RT inhibitor mutations, 3 (4%) had all but 3 RT inhibitor mutations, and 3 (4%) had all but 4 RT inhibitor mutations. Phenotypic testing of 29 clones showed that most clones were resistant to nearly all NRTIs and that those with NNRTI resistance mutations were also resistant to multiple NNRTIs. These data show that in heavily treated persons, most RT inhibitor resistance mutations are present in the same viral genomes (colinear) and that multidrug resistance often occurs within individual clones as well as within virus populations.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14615657      PMCID: PMC2573396          DOI: 10.1097/00126334-200312010-00006

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  21 in total

1.  Analysis of HIV type 1 reverse transcriptase: comparing sequences of viral isolates with mutational data.

Authors:  J A Wrobel; M J Conrad; E Bloedon; R Swanstrom; C A Hutchison
Journal:  AIDS Res Hum Retroviruses       Date:  2000-12-10       Impact factor: 2.205

2.  Reproducibility of human immunodeficiency virus type 1 (HIV-1) protease and reverse transcriptase sequencing of plasma samples from heavily treated HIV-1-infected individuals.

Authors:  R W Shafer; A Warford; M A Winters; M J Gonzales
Journal:  J Virol Methods       Date:  2000-05       Impact factor: 2.014

Review 3.  HIV drug resistance and viral fitness.

Authors:  F Clavel; E Race; F Mammano
Journal:  Adv Pharmacol       Date:  2000

4.  Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication, and protein maturation of antiretroviral drug-resistant human immunodeficiency virus type 1.

Authors:  G Bleiber; M Munoz; A Ciuffi; P Meylan; A Telenti
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

5.  A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V.

Authors:  K Hertogs; S Bloor; V De Vroey; C van Den Eynde; P Dehertogh; A van Cauwenberge; M Stürmer; T Alcorn; S Wegner; M van Houtte; V Miller; B A Larder
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

6.  Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy.

Authors:  A J Hance; V Lemiale; J Izopet; D Lecossier; V Joly; P Massip; F Mammano; D Descamps; F Brun-Vézinet; F Clavel
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

7.  Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity.

Authors:  Kirsten L White; Nicolas A Margot; Terri Wrin; Christos J Petropoulos; Michael D Miller; Lisa K Naeger
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

8.  Underestimation of HIV type 1 drug resistance mutations: results from the ENVA-2 genotyping proficiency program.

Authors:  Rob Schuurman; Donald Brambilla; Tom de Groot; Diana Huang; Sally Land; James Bremer; Ireen Benders; Charles A B Boucher
Journal:  AIDS Res Hum Retroviruses       Date:  2002-03-01       Impact factor: 2.205

9.  A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1.

Authors:  C J Petropoulos; N T Parkin; K L Limoli; Y S Lie; T Wrin; W Huang; H Tian; D Smith; G A Winslow; D J Capon; J M Whitcomb
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

10.  Relative replication fitness of a high-level 3'-azido-3'-deoxythymidine-resistant variant of human immunodeficiency virus type 1 possessing an amino acid deletion at codon 67 and a novel substitution (Thr-->Gly) at codon 69.

Authors:  T Imamichi; S C Berg; H Imamichi; J C Lopez; J A Metcalf; J Falloon; H C Lane
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

View more
  5 in total

1.  Panel of prototypical infectious molecular HIV-1 clones containing multiple nucleoside reverse transcriptase inhibitor resistance mutations.

Authors:  Elizabeth Johnston; Kathryn M Dupnik; Matthew J Gonzales; Mark A Winters; Soo-Yon Rhee; Tomozumi Imamichi; Robert W Shafer
Journal:  AIDS       Date:  2005-04-29       Impact factor: 4.177

2.  Development of elvitegravir resistance and linkage of integrase inhibitor mutations with protease and reverse transcriptase resistance mutations.

Authors:  Mark A Winters; Robert M Lloyd; Robert W Shafer; Michael J Kozal; Michael D Miller; Mark Holodniy
Journal:  PLoS One       Date:  2012-07-18       Impact factor: 3.240

3.  Viral population estimation using pyrosequencing.

Authors:  Nicholas Eriksson; Lior Pachter; Yumi Mitsuya; Soo-Yon Rhee; Chunlin Wang; Baback Gharizadeh; Mostafa Ronaghi; Robert W Shafer; Niko Beerenwinkel
Journal:  PLoS Comput Biol       Date:  2008-05-09       Impact factor: 4.475

4.  Aptamers that recognize drug-resistant HIV-1 reverse transcriptase.

Authors:  Na Li; Yuxuan Wang; Arti Pothukuchy; Angel Syrett; Naeem Husain; Siddharth Gopalakrisha; Pradeepa Kosaraju; Andrew D Ellington
Journal:  Nucleic Acids Res       Date:  2008-10-23       Impact factor: 16.971

5.  Dual inhibition of HIV-1 replication by integrase-LEDGF allosteric inhibitors is predominant at the post-integration stage.

Authors:  Erwann Le Rouzic; Damien Bonnard; Sophie Chasset; Jean-Michel Bruneau; Francis Chevreuil; Frédéric Le Strat; Juliette Nguyen; Roxane Beauvoir; Céline Amadori; Julie Brias; Sophie Vomscheid; Sylvia Eiler; Nicolas Lévy; Olivier Delelis; Eric Deprez; Ali Saïb; Alessia Zamborlini; Stéphane Emiliani; Marc Ruff; Benoit Ledoussal; François Moreau; Richard Benarous
Journal:  Retrovirology       Date:  2013-11-21       Impact factor: 4.602

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.